The Top Biopharma Events to Watch in 2020
Here, 24/7 Wall St. presents a calendar of a few of the biggest clinical trial and FDA updates to watch for in early 2020.
All Work
Chris Lange
Why This Hairy Cell Leukemia Treatment Could Be Big in Europe
Innate Pharma shares jumped on Thursday after the firm announced that the European Medicines Agency has accepted the Marketing Authorization Application for Lumoxiti for adult patients with relapsed or refractory hairy cell leukemia.
Why One Analyst Thinks 2020 Could Be Huge for Amazon
Independent research firm Argus notes that the number of Amazon items delivered with Prime one-day and Prime same-day delivery nearly quadrupled from the prior year.
Why This Refractory Angina Treatment Could Be a Big Hit
Neovasc shares nearly doubled on Tuesday after the firm announced the submission of an application to the FDA for its Neovasc Reducer medical device for the treatment of refractory angina.
Is It Over for This Huntington’s Disease Clinical Trial?
Wave Life Sciences shares dropped sharply to start out the week after the company announced topline data from its ongoing midstage trial in Huntington’s disease.
Why One Analyst Sees Sarepta’s Roche Deal Taking Off
Sarepta shares jumped last week on news that the company reached a licensing deal with Roche. While investors saw about a five-point bump from this news, one analyst sees much more upside for this…
Wedbush’s Top 10 Tech Predictions for 2020
Wedbush believes that there is clear momentum for the tech stocks in 2020 as a number of transformational trends such as 5G, cloud, autonomous and the streaming content wars will be front and center.
Why This aPAP Treatment Is a Big Hit
Savara shares more than doubled on Monday after the firm announced that the FDA has granted Breakthrough Therapy designation for its autoimmune pulmonary alveolar proteinosis treatment Molgradex.
AstraZeneca’s FDA Nod Could Be Big
AstraZeneca has announced that the FDA has approved its companion diagnostic test that identifies patients with metastatic pancreatic cancer.
Disney Makes Case for Being Legitimate Death Star in US Box Office
Disney topped the weekend box office for the second straight time, notching a cool $72 million in North American ticket sales.
The Worst Performing Retailers of 2019
24/7 Wall St. has put together a list of retailers that have suffered the most in 2019.
Why This Uriniary Tract Infection Trial Could Be Huge
Iterum Therapeutics shares more than doubled on Friday after the firm announced that it had completed the enrollment of its late-stage clinical trial in uncomplicated urinary tract infections.
Is This a Buying Opportunity for Cannabis ETFs Going Into 2020?
Many investors are focused on getting the jump on the cannabis industry, but they aren’t alone. With this increased speculation, there is added risk that has to be considered.
Will a Record National Returns Day Hurt Amazon?
In a note Thursday, UPS said that it forecasts a record National Returns Day, with 1.9 million returns expected, up 26% from last year. This will be the seventh consecutive record National Returns Day…
Why This China Deal Is Huge for Pintec
Pintec Technology shares nearly doubled on Friday after the firm announced an agreement with China Unicom to expand its offerings.
Why This Osteoarthritis Treatment Is Making Waves
Flexion Therapeutics shares popped on Friday after the company announced that the FDA has approved a supplemental New Drug Application to update the product label for Zilretta for the treatment of osteoarthritis knee pain.
The Top Healthy Living ETFs of 2019
Eating a nutritious and well-balanced diet, exercising regularly and abstaining from bad habits like smoking greatly increase one’s odds of living a long and healthy life. With these trends gaining ever more traction, they…
Could This Breast Cancer Study Be the Next Big Thing?
Immunomedics shares made a handy gain on Thursday after the company announced that the FDA has accepted its Biologics License Application for its breast cancer treatment.
Why This Cancer Study Is Crushing Spectrum Pharma
Spectrum Pharma shares were halved on Thursday after the firm provided an update on its midstage cancer study some updates on its late-stage programs with the FDA.
Is Semiconductor Short Interest Signaling Further Market Highs?
The December 13 short interest data have been compared with the previous report. Short interest in most of these selected semiconductor stocks decreased.